[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"asthma-in-children\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:asthma-in-children":25},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,61,0,25,[9,41,66,95,120,146,179,208,228,251,272,293,340,365,384,407,444,466,488,512,532,559,585,608,631],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100053873","y-of-central-maryland-head-start-asthma-implementation-100053873",false,"NCT05004714","Y of Central Maryland Head Start Asthma Implementation","Implementation of a Multilevel Program to Reduce Asthma Symptoms in Urban Preschoolers","Aim 1\n\nInclusion Criteria:\n\n* Aged 18 or older\n* Head Start Staff member or caregiver of child currently enrolled in Head Start with asthma\n* Cognitive ability to provide consent\n* Willing to be audio recorded","ALL","18 Years",{"count":20,"type":21},500,"ESTIMATED","OBSERVATIONAL","Despite a strong evidence-base for the efficacy of multilevel programs in reducing asthma symptoms among low-income preschool minority children, gaps remain in our understanding of how to best translate and scale up these efficacious interventions into sustainable programs that reduce known asthma health disparities. Head Start (HS) serves over one million low income children in the US each year by focusing on early learning, physical health, and family engagement. HS is committed to implementing evidence based programs to promote overall child well-being, and is focused on addressing asthma symptoms due to the deleterious impact on school absences and child development. We have demonstrated the effectiveness of a multi-level staff and family education program (ABC Asthma) that significantly reduced asthma symptoms and courses of oral corticosteroids. However, these interventions are not successfully integrated within community organizations for long-term sustainability. It is unknown how to best scale up and implement these evidence based asthma interventions into low resource community organizations that serve children at risk. Implementation strategies are frequently developed atheoretically and may not be tailored to the setting. The overall purpose of this project is to inform best practices of implementation of an asthma education program by 1) systematically evaluating the use of intervention mapping to develop a tailored implementation strategy in partnership with Head Start stakeholders, 2) examining both staff and organizational level determinants associated with implementation of ABC Asthma, and 3) evaluating the success of tailored implementation strategies on implementation outcomes and school absences and other health outcomes. The YMCA of Central Maryland have enthusiastically agreed to implement the Maryland ABC HS Asthma within 40 sites in four communities: Baltimore City, Baltimore County, Anne Arundel County, and Prince George's County.",[25,26,27],"Asthma in Children","Implementation","Preschool Children","RECRUITING","2026-07-10",{"date":31,"type":32},"2026-07-13","ACTUAL",{"date":34,"type":32},"2020-08-01",{"date":36,"type":21},"2027-07-31",{"name":38,"class":39},"Johns Hopkins University","OTHER",2,{"id":42,"slug":43,"hasResults":12,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":12,"sex":17,"minAge":48,"maxAge":18,"enrollmentInfo":49,"targetDuration":4,"studyType":50,"phases":51,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":63,"locationsCount":65},"100528312","smarthome-feasibility-trial-100528312","NCT06159127","SMART@Home Feasibility Trial","Self-Management Assistance for Recommended Treatment (SMART)@Home Care","Inclusion Criteria:\n\n* Patients diagnosed with a chronic medical condition requiring regular treatment, i.e., asthma\n* Ages 12-18\n* English fluency for patient and caregiver\n\nExclusion Criteria:\n\n* Diagnosis of pervasive developmental disorder in patient or caregiver as determined by medical chart review\n* Diagnosis of serious mental illness (e.g., schizophrenia) in patient or caregiver as determined by medical chart review","12 Years",{"count":7,"type":21},"INTERVENTIONAL",[52],"NA","The proposed research addresses the limitations or lack of a digital platform to provide remote care of medically complex patients. Previous attempts have had poor clinical validity and suffered lack of patient engagement. The study team will deconstruct the previously implemented SMART platforms to create a roadmap, platform, and template to guide clinicians to create new tools.\n\nResults from Phase 1 of this project highlighted the need for connectivity between the SMART@Home app and Bluetooth-enable devices to provide objective disease activity data as well as integration with Epic electronic health record so that providers can use the data to inform treatment planning and decision making. A subsequent pilot user validation trial is also needed to confirm development goals were met. Conducting a pilot user validation trial of the SMART@Home asthma tracker, spirometer, and action plan is the purpose of the next phases of this study.\n\nA beta test the SMART@Home Asthma Tracker and asthma action plan algorithm will take place with approximately 8 participants. Beta testing will have participants record simulated increases in symptoms to ensure appropriate levels of care is communicated via the app. Then, a group of 40 adolescent (ages 12-17) patients with asthma for a 6-month pilot Randomized Control Trial (RCT). Participants will be randomized into either the IMAAP SMART@Home (n=20) or control (n=20) groups following the completion of baseline measures to test the interactive asthma action plan functionality and impact.",[55,25],"Asthma",[55],"2026-06-30",{"date":59,"type":32},"2026-07-02",{"date":61,"type":32},"2024-09-09",{"date":36,"type":21},{"name":64,"class":39},"Children's Hospital Medical Center, Cincinnati",1,{"id":67,"slug":68,"hasResults":12,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":12,"sex":17,"minAge":73,"maxAge":74,"enrollmentInfo":75,"targetDuration":4,"studyType":50,"phases":77,"briefSummary":78,"conditions":79,"keywords":81,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":65},"100557530","project-asthma---aligning-with-schools-to-help-manage-asthma-and-improve-outcomes-100557530","NCT06539312","Project ASTHMA - Aligning With Schools To Help Manage Asthma and Improve Outcomes","Project ASTHMA - Aligning With Schools To Help Manage Asthma and Decrease Health Inequities","Inclusion Criteria:\n\n* uncontrolled asthma\n\nExclusion Criteria:\n\n* other chronic lung disease such as cystic fibrosis","4 Years","13 Years",{"count":76,"type":21},400,[52],"Children with asthma from communities that experience health inequities frequently do not receive guideline-based asthma care, and as a result, account for a disproportionate percentage of asthma exacerbations, emergency department visits, and hospitalizations. Project ASTHMA (Aligning with Schools To Help Manage Asthma) tests the effectiveness of school-based health centers as a delivery model to improve health outcomes by providing children with guideline-based asthma assessments and preventive medication management, directly observed therapy of their preventive medication to support adherence, and self-management support. If successful, this multicomponent intervention will represent a cost effective and sustainable model to reduce asthma morbidity in historically marginalized communities, and has the potential to impact communities throughout the United States where over 2,500 school-based health centers operate.",[25,80],"Directly Observed Therapy",[55,82,83,84,85,80],"Children","School-based health center","NIH Guideline-based care","Controller medication","2026-06-22",{"date":88,"type":32},"2026-06-25",{"date":90,"type":32},"2024-09-27",{"date":92,"type":21},"2028-04-30",{"name":94,"class":39},"State University of New York at Buffalo",{"id":96,"slug":97,"hasResults":12,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":4,"eligibilityCriteria":101,"healthyVolunteers":12,"sex":17,"minAge":102,"maxAge":103,"enrollmentInfo":104,"targetDuration":4,"studyType":50,"phases":106,"briefSummary":107,"conditions":108,"keywords":4,"overallStatus":109,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":65},"100642714","scaling-up-the-integrated-care-pathway-for-acute-asthma-to-all-osakidetza-pediatric-services-through-a-cluster-randomized-smart-design-100642714","NCT07642388","Scaling up the Integrated Care Pathway for Acute Asthma to All Osakidetza Pediatric Services Through a Cluster-randomized SMART Design","Scaling up the Integrated Care Pathway for Acute Asthma to All Osakidetza Pediatric Services Through a Cluster-randomized Sequential, Multiple Assignment, Randomized Trial (SMART) Design","Eligibility for healthcare settings:\n\n\\- All Pediatric Services (Primary Care n=108 and Hospital Care n=9) from 11 of the 13 Osakidetza Integrated Healthcare Organizations that are not currently implementing the ASMAbat Pathway.\n\nEligibility for professionals:\n\n* Primary Care pediatricians and nurses\n* Pediatricians and nurses in the Pediatric Emergency Department\n* Pediatricians and nurses on the inpatient ward\n* Pediatric Intensive Care pediatricians and nurses\n* Pediatric Pneumology pediatricians and nurses\n\nEligibility for patients:\n\nPatients between 2 and 14 years that have being attended between the 1st of July 2026 and the 28th of February 2029, and with an acute episode of asthma, defined as:\n\n* an episode of wheezing and a previous diagnosis of asthma or with a previous episode of wheezing\n* a first episode in a child older than 2 years with a personal\u002Ffamily history of atopy and\u002For with an objective response to bronchodilators as assessed by a severity Score","2 Years","14 Years",{"count":105,"type":21},4680,[52],"The main goal of this study is to evaluate the effectiveness of adaptive sequential implementation strategies based on facilitation in promoting the sustainable and widespread adoption and scaling up of the Integrated Care Pathway for Acute Asthma - ASMAbat across all Primary Care and Hospital Pediatric Services of Osakidetza - Basque Health Service.",[25],"NOT_YET_RECRUITING","2026-06-15",{"date":112,"type":32},"2026-06-16",{"date":114,"type":21},"2026-07-01",{"date":116,"type":21},"2029-02-28",{"name":118,"class":119},"Basque Health Service","OTHER_GOV",{"id":121,"slug":122,"hasResults":12,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":4,"eligibilityCriteria":126,"healthyVolunteers":12,"sex":17,"minAge":48,"maxAge":18,"enrollmentInfo":127,"targetDuration":4,"studyType":50,"phases":129,"briefSummary":130,"conditions":131,"keywords":133,"overallStatus":109,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":40},"100632356","asthma-ctrl-smart-trial-100632356","NCT07512622","Asthma Ctrl SMART Trial","Improving Medication Adherence Using an Adaptive mHealth Intervention in Adolescents With Asthma.","Inclusion Criteria:\n\n* Patient age between 12-18 years\n* Patient is diagnosed with severe-persistent or moderate-persistent asthma per NAEPP asthma guidelines\n* Patient is prescribed at least one daily inhaled controller medication or a daily combination inhaled corticosteroid and long-acting beta-agonist and a beta-agonist bronchodilator\n* English fluency for patient, caregiver, and clinician\n\nExclusion Criteria:\n\n* Significant cognitive deficits that may interfere with comprehension per medical team or chart review\n* Diagnosis of serious mental illness (e.g., schizophrenia)\n* Diagnosis of pervasive developmental disorder\n* Active chronic disease apart from asthma or allergic disease (e.g. Bronchiectasis, pulmonary hypertension, and moderate or severe tracheomalacia)\n* Patient receives school administered daily controller medication at the time of the enrollment visit",{"count":128,"type":21},389,[52],"The primary objective is to examine the efficacy of an mHealth adherence intervention (Asthma Ctrl) on adherence to daily inhaled corticosteroids as measured by electronically monitored adherence in adolescents with asthma. The secondary objective is to compare the effectiveness of three intervention strategies: 1. asthma management app (control); 2. Asthma Ctrl; 3. Asthma Ctrl+ on adherence, lung function, and health care utilization at post-intervention and 1- and 6-month follow-up. The third objective is to explore and contrast different challenges and combinations of challenges to identify which are most impactful in determining response to the three intervention strategies.",[25,132],"Asthma Chronic",[134,135,136,137],"sequential, multiple assignment, randomized trial (SMART)","adherence","asthma","adolescents","2026-05-08",{"date":140,"type":32},"2026-05-11",{"date":142,"type":21},"2026-05-30",{"date":144,"type":21},"2030-06-01",{"name":64,"class":39},{"id":147,"slug":148,"hasResults":12,"nctId":149,"briefTitle":150,"officialTitle":151,"acronym":152,"eligibilityCriteria":153,"healthyVolunteers":154,"sex":17,"minAge":4,"maxAge":155,"enrollmentInfo":156,"targetDuration":4,"studyType":50,"phases":158,"briefSummary":159,"conditions":160,"keywords":166,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":65},"100540001","early-life-intervention-in-pediatrics-supported-by-e-health---smoke-100540001","NCT06311162","Early Life Intervention in Pediatrics Supported by E-health - SMOKE","Early Life Intervention in Pediatrics Supported by E-health (ELIPSE II): Coaching Parents to Lower Second-hand Smoke Exposure in Children A Single-blind Randomized Controlled Parallel-group Clinical Trial","ELIPSE-II","Inclusion Criteria:\n\n* Age: younger than 6 years\n* Exposed to second-hand smoke at home (at least one parent smoking)\n* German speaking parent\n* All sex and ethnic backgrounds\n* Signed informed consent form from parent\n* Children live\u002Fgrow-up in the same household as the parental participant\n* Referred by a health care professional (e.g. physician, midwife, nurse, other professions)\n\nExclusion Criteria:\n\n* Participation in another study\u002Ftrial targeting similar outcomes\n* Participation in an active smoking cessation programme",true,"5 Years",{"count":157,"type":21},160,[52],"Unrestricted parental smoking habits are lifestyle risk behaviors associated with chronic, systemic inflammation, which promotes the pathogenesis of non-communicable diseases (NCDs). Exposure to secondhand tobacco smoke in early life contributes to the development of specific NCDs in children, i.e. asthma. Early preventive measures to improve lifestyle behavior in parents are therefore of utmost importance. The aim of ELIPSE-II is to assess whether an eHealth application intervention for parents is feasible and efficacious in lowering levels of urinary cotinine as a measure of second-hand smoke exposure in their children .",[161,25,162,163,164,165],"Smoking Reduction","Wheezing","Non-Communicable Disease","Life Style","Behavior, Smoking",[167,82,168,169],"Secondhand smoke","Prevention","eHealth","2026-04-30",{"date":172,"type":32},"2026-05-06",{"date":174,"type":32},"2024-05-07",{"date":176,"type":21},"2028-12-31",{"name":178,"class":39},"Insel Gruppe AG, University Hospital Bern",{"id":180,"slug":181,"hasResults":12,"nctId":182,"briefTitle":183,"officialTitle":183,"acronym":184,"eligibilityCriteria":185,"healthyVolunteers":12,"sex":17,"minAge":186,"maxAge":187,"enrollmentInfo":188,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":190,"conditions":191,"keywords":194,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":207},"100593819","diagnosing-asthma-with-clinically-accessible-non-invasive-and-efficient-tests-a-child-inclusive-translational-investigation-100593819","NCT07011394","Diagnosing Asthma With Clinically Accessible, Non-invasive, and Efficient Tests: a Child-inclusive Translational Investigation","DIVE 2","Inclusion Criteria:\n\n* Individuals aged 6 to \\\u003C18 years, presenting symptoms suggestive of asthma\n* Patients referred for a methacholine bronchial provocation test by primary care (defined as non-pulmonologist, non-ENT specialist, non-allergist)\n* Spirometry inconclusive\n\nExclusion Criteria:\n\n* Use of an inhaled or systemic corticosteroid in the previous 48 hours;\n* Smoking in the previous 6 hours; history of viral and\u002For bacterial respiratory infection in the past 4 weeks;\n* major cardiopulmonary disease, including: a) chronic obstructive pulmonary disease (COPD), defined by all of the following: i) aged ≥ 40 years , ii) permanent obstruction on spirometry (FEV1\u002FFVC \\\u003C0.7) and iii) a smoking history of \\>10 pack-years or known alpha-1-antitrypsin deficiency, b) lung conditions deemed significant by the investigator, including cystic fibrosis and bronchiectasis, and c) unstable heart disease.","6 Years","17 Years",{"count":189,"type":21},123,"Asthma is a common inflammatory respiratory disease affecting 11% of Canadians, but its diagnosis remains challenging, leading to delays in treatment or overtreatment. Spirometry with a reversibility test and bronchial provocation testing (BPT), considered the gold standard, are the reference diagnostic methods. However, access to BPT is limited as it is performed in hospital settings.\n\nType 2 inflammation biomarkers, the fractional exhaled nitric oxide (FeNO) and blood eosinophils (EOS), represent a potential alternative. In addition to their prognostic and theragnostic value, these markers predict a good response to inhaled corticosteroids in individuals aged ≥ 6 years with asthma. However, their use remains restricted to pulmonologists in specialized clinics and is not recommended as a diagnostic tool in Quebec.\n\nDespite studies demonstrating their diagnostic value in specialized settings, these tests remain underexplored in primary care and insufficiently studied in children under 12 years.\n\nThe objective of ou study is to evaluate the relevance and performance of FeNO and blood eosinophils in the diagnosis of asthma in children referred in primary care with non-diagnostic spirometry.",[192,193,25,55],"Diagnosis","Inflammation",[195,196,197,198],"observationnal study","asthma diagnosis","FeNO and eosinophil blood count","children","2026-04-29",{"date":172,"type":32},{"date":202,"type":32},"2024-04-09",{"date":204,"type":21},"2027-07-01",{"name":206,"class":39},"Université de Sherbrooke",3,{"id":209,"slug":210,"hasResults":12,"nctId":211,"briefTitle":212,"officialTitle":212,"acronym":213,"eligibilityCriteria":214,"healthyVolunteers":12,"sex":17,"minAge":186,"maxAge":4,"enrollmentInfo":215,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":217,"conditions":218,"keywords":219,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":223,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":227,"locationsCount":207},"100591495","propulsion-sante-inflammometry-to-improve-the-diagnostic-trajectory-in-situations-of-suspected-asthma-in-children-and-adults-100591495","NCT06981169","PROPULSION SANTE: Inflammometry to Improve the Diagnostic Trajectory in Situations of Suspected Asthma in Children and Adults","PROPULSION","Inclusion Criteria:\n\n* patients age 6 and older\n* referred by primary care ofr an asthma diagnostic test (spirometry or methacholine challenge)\n\nExclusion Criteria:\n\n* referred by pulmonologist",{"count":216,"type":21},1500,"The objective of this observational study is to assess the relevance of inflammometry (based on the measurement of fractional exhaled nitric oxide (FeNO) and blood eosinophil count (BEC)) as a tool for prioritizing respiratory diagnostic tests.\n\nThe study will evaluate the role of inflammometry (FeNO and BEC) in prioritizing diagnostic respiratory tests. It will include patients aged six and older with suspected asthma, referred by non-pulmonologists for diagnostic asthma testing (spirometry or methacholine challenge test) at three hospital centers: Sherbrooke University Hospital Center (CHUS), Sainte-Justine University Hospital Center (CHU Sainte-Justine), and the Montreal Children's Hospital.\n\nThe hypothesis is that using inflammometry as a prioritization tool would reduce diagnostic delays for high-risk patients with elevated biomarkers. This study could help shorten wait times, relieve congestion in diagnostic testing queues, and improve the diagnostic pathway. Additionally, it would enhance the interpretation of pulmonary function test results by incorporating inflammometry findings, leading to better patient stratification.\n\nPatients referred from primary care will undergo pulmonary function testing (spirometry ± methacholine challenge) and, as part of the study:\n\nFeNO measurement using a portable device Blood test for eosinophil count Questionnaire on asthma control and quality of life, completed at the visit and at follow-ups at 4, 8, and 12 months",[55,193,25],[192,55,220,221,222],"inflammation","FeNO","Blood eosinophil count",{"date":170,"type":32},{"date":225,"type":32},"2025-03-24",{"date":204,"type":21},{"name":206,"class":39},{"id":229,"slug":230,"hasResults":12,"nctId":231,"briefTitle":232,"officialTitle":233,"acronym":234,"eligibilityCriteria":235,"healthyVolunteers":12,"sex":17,"minAge":236,"maxAge":48,"enrollmentInfo":237,"targetDuration":4,"studyType":50,"phases":239,"briefSummary":240,"conditions":241,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":243,"startDateStruct":245,"completionDateStruct":247,"leadSponsor":249,"locationsCount":65},"100504177","telehealth-enhanced-asthma-care-for-home-after-the-emergency-room-100504177","NCT05844891","Telehealth-Enhanced Asthma Care for Home After the Emergency Room","Telehealth-Enhanced Asthma Care for Home After the Emergency Room (TEACH-ER)","TEACH-ER","Inclusion Criteria (all criteria must be met):\n\n* Physician diagnosis of asthma, based on review of medical records and\u002For caregiver report.\n* Current emergency visit for an acute asthma exacerbation, requiring treatment with rescue medication.\n* Persistent asthma or poor asthma control for which a daily controller medication is recommended by NHLBI guidelines, defined as any 1 of the following:\n\n  1. \\>2 days\u002Fwk with asthma symptoms in the past month,\n  2. \\>2 days\u002Fwk with rescue medication use in the past month,\n  3. \\>2 days\u002Fmonth with nighttime symptoms in the past month (vs. 1-2 nights per month if 3-4 years old), or\n  4. ≥1 other episode of asthma during the past year that required systemic corticosteroids (vs. during the past 6 months if 3-4 years old).\n* Child age between ≥3 and ≤12 years.\n* Child and caregiver live in the greater Rochester, NY metropolitan area (Monroe, Wayne, Ontario, Livingston, Genesee, and Orleans Counties)\n* Emergency severity index triage scores of 2-5 (total range 1-5; scores of 1 indicate the highest acuity and likelihood of hospitalization).\n\nExclusion Criteria:\n\n* An inability to speak and understand English. Parents (and children) with low literacy \u002F health-literacy skills will be eligible, as survey instruments will be administered verbally and educational materials will be designed for low-literacy populations.\n* No access to a working phone for follow-up surveys (either at the subject's home or an easily accessible location). If a subject does not have access to an appropriate device for Zoom visits at home, we will provide a device with required data plan.\n* Other significant medical conditions, including cystic fibrosis, congenital heart disease, or other chronic lung disease, that could interfere with the assessment of asthma-related measures.\n* Children in foster care or other situations in which consent cannot be obtained from a legal guardian.","3 Years",{"count":238,"type":21},430,[52],"The investigators propose a randomized controlled trial of Telehealth-Enhanced Asthma Care for Home After the Emergency Room (TEACH-ER) vs. enhanced care (EC). TEACH-ER includes: 1) brief, pictorial, and health literacy-informed asthma education in the ED, with color- and shape-coded labels provided for home asthma medications; 2) virtual primary care follow-up within 1 week of discharge using in-home telemedicine (Zoom) when possible, featuring provider prompts for guideline-based preventive therapy and home delivery of prescribed medications with pictorial action plans; 3) two additional in-home virtual visits to reinforce teaching, review treatment plans, label medications, and support effective management practices. The investigators will enroll 430 children (ages 3-12 yrs) from the two dedicated pediatric EDs in our region, and follow all participants for a 12-month period. The investigators will call caregivers to complete blinded follow-up telephone surveys at 3, 6, 9, and 12 months after discharge. The investigators will assess the effectiveness of TEACH-ER in reducing the need for additional asthma-related ED visits or hospitalizations in the 1-months after enrollment. Additional outcomes of interest include asthma symptoms, medication adherence, absenteeism from work and school, quality of life, and the delivery of care consistent with national asthma care guidelines.",[25],"2026-04-28",{"date":244,"type":32},"2026-05-04",{"date":246,"type":32},"2024-04-01",{"date":248,"type":21},"2028-06-30",{"name":250,"class":39},"University of Rochester",{"id":252,"slug":253,"hasResults":12,"nctId":254,"briefTitle":255,"officialTitle":256,"acronym":257,"eligibilityCriteria":258,"healthyVolunteers":12,"sex":17,"minAge":73,"maxAge":48,"enrollmentInfo":259,"targetDuration":4,"studyType":50,"phases":261,"briefSummary":262,"conditions":263,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":265,"startDateStruct":266,"completionDateStruct":268,"leadSponsor":270,"locationsCount":65},"100610167","promoting-asthma-management-guidelines-with-technology-based-intervention-and-care-coordination-in-clinics-and-schools-100610167","NCT07224061","Promoting Asthma Management Guidelines With Technology-Based Intervention and Care Coordination in Clinics and Schools","Promoting Asthma Guidelines and Management Through Technology-Based Intervention and Care Coordination in Clinics and Schools (PRAGMATIC-S)","PRAGMATIC-S","Inclusion Criteria:\n\n* Physician-diagnosed asthma documented in EHR\n* Persistent asthma, not on controller medications or uncontrolled asthma despite therapy (with any one of the following per age-specific guidelines: in past month, \\>2 days\u002Fweek with symptoms, \\>2 days\u002Fweek using rescue medication, \\>2 days\u002Fmonth with nighttime symptoms, or \\>2 episodes\u002Fyear that required systemic corticosteroids\n* Age 4 to 12 years, inclusive, attending pre-kindergarten through 7th grade in public \u002F charter \u002F private schools in New York City (the Bronx primarily) and also schools in lower Hudson Valley (Eastchester, Westchester, Rockland, Yonkers)\n* Caregiver is able to speak and understand either English or Spanish. Participants unable to read will be eligible as all surveys will be administered verbally by research personnel\n* Consent from primary caregiver and assent from child (age ≥7 years). If there are eligible siblings with exact same asthma severity\u002Fcontrol screening results, one child will be randomly selected to participate, otherwise the sibling with worse asthma symptoms will be selected.\n* Presence of a phone to conduct surveys and smartphone, iPad or computer to electronically complete and e-sign MAF\n\nExclusion Criteria:\n\n* Family plans to leave school or city within 6 months\n* Significant medical conditions (e.g., congenital heart disease, cystic fibrosis, or other chronic lung disease)\n* Children in foster care or other situations in which consent cannot be obtained from a legal guardian\n* Participation in concurrent asthma intervention study\n* Severe developmental delay (e.g., severe autism) precluding completion of asthma control questionnaire",{"count":260,"type":21},420,[52],"The overall goal of this research study is to evaluate a multi-level program called PRAGMATIC-S to improve the delivery of guideline-based asthma care through a unique partnership between clinical practices and schools. PRAGMATIC-S represents a novel approach that addresses multiple barriers to adherence by bridging primary care and schools, ensuring delivery of guideline-based asthma care to urban children across these settings thereby improving adherence to therapy and clinical outcomes.",[25],"2026-04-23",{"date":199,"type":32},{"date":267,"type":32},"2026-02-12",{"date":269,"type":21},"2033-06-30",{"name":271,"class":39},"Montefiore Medical Center",{"id":273,"slug":274,"hasResults":12,"nctId":275,"briefTitle":276,"officialTitle":276,"acronym":4,"eligibilityCriteria":277,"healthyVolunteers":12,"sex":17,"minAge":155,"maxAge":48,"enrollmentInfo":278,"targetDuration":4,"studyType":50,"phases":280,"briefSummary":281,"conditions":282,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":283,"lastUpdatePostDateStruct":284,"startDateStruct":286,"completionDateStruct":288,"leadSponsor":290,"locationsCount":292},"100516365","reducing-asthma-attacks-in-disadvantaged-school-children-with-asthma-100516365","NCT06003569","Reducing Asthma Attacks in Disadvantaged School Children With Asthma","Inclusion Criteria:\n\n* students with poor asthma control (or indicators of excess burden on school Asthma Intake Form)\n* age 5-12 years of age\n* attending one of participating schools in rural Colorado (school selection criteria: high rates of socioeconomic need based on high rates of free-and-reduced lunch or rural status)\n\nExclusion Criteria:\n\n* age \\\u003C 5 years or \\> 12 years\n* students with no or controlled asthma",{"count":279,"type":21},300,[52],"Our UH3 clinical trial, \"Reducing Asthma Attacks in Disadvantaged School Children with Asthma,\" seeks broad-scale implementation of our effective school-based approach to improve asthma disparities for children, ages 5-12 years, in low-income communities. The investigators will contextualize dissemination and implementation (D\\&I) of our Colorado school-based asthma program (Col-SBAP) that reduces asthma exacerbations and missed school days, while also addressing social determinants of health. Our Better Asthma Control for Kids (BACK) Program will evaluate key metrics identified by diverse stakeholders during this dissemination trial in rural and small metropolitan areas of Colorado. Our clinical trial includes two implementation strategies: our standard Col-SBAP, titled BACK-Standard (BACK-S) and an enhanced community-centered approach, titled Back-Enhanced (BACK-E). These two strategies are designed for sustainable delivery by school asthma navigators and school nurses who coordinate with primary care and community resources. The Exploration, Preparation, Implementation, Sustainment (EPIS) D\\&I framework was applied with community partners during the UG3 planning phase to tailor implementation plans that meet local community needs, resources and priorities (EPIS Phases 1 \\& 2). BACK-S and BACK-E will be delivered from years 1-3 with data collection for implementation and effectiveness outcomes in 4 Colorado regions. In year 4, the investigators will collect data for sustainment outcomes (EPIS phase 3). The investigators will apply the work from EPIS phases 1-3 to refine our \"dissemination playbook\" that guides adoption by other school systems (EPIS Phase 4). Our primary implementation hypothesis is: Reach will be greater among students when delivered using the BACK-E arm as compared to BACK-S. Our effectiveness hypothesis is: BACK will be more effective than usual care at reducing asthma exacerbations. The BACK playbook includes training materials and a calculation of return on investment. The investigators are targeting schools with high levels of uncontrolled asthma and asthma associated burden. Our UH3 trial includes partner engagement to ensure BACK is disseminated to diverse geopolitical areas of Colorado with attention to sustainability. Collectively, our approach will accelerate dissemination of BACK nationally to communities experiencing health inequities in pediatric asthma care.",[25],"2026-04-06",{"date":285,"type":32},"2026-04-13",{"date":287,"type":32},"2023-09-21",{"date":289,"type":21},"2027-08",{"name":291,"class":39},"University of Colorado, Denver",13,{"id":294,"slug":295,"hasResults":12,"nctId":296,"briefTitle":297,"officialTitle":298,"acronym":299,"eligibilityCriteria":300,"healthyVolunteers":154,"sex":17,"minAge":301,"maxAge":302,"enrollmentInfo":303,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":305,"conditions":306,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":331,"lastUpdatePostDateStruct":332,"startDateStruct":333,"completionDateStruct":335,"leadSponsor":337,"locationsCount":339},"100383878","pharmacokinetics-pharmacodynamics-and-safety-profile-of-understudied-drugs-administered-to-children-per-standard-of-care-pops-100383878","NCT04278404","Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)","Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs","POPS or POP02","Inclusion Criteria:\n\n1. Participant is \\\u003C 21 years of age\n2. Parent\u002F Legal Guardian\u002F Adult Participant can understand the consent process and is willing to provide informed consent\u002FHIPAA:\n3. (a) Participant is receiving one or more of the study drugs of interest at the time of enrollment or (b) Participant is NOT receiving one or more of the study drugs of interest but is SARS-COV-2 positive within 60 days prior to enrollment\n\nExclusion Criteria:\n\n1. Participant has a known pregnancy\n\n   Below exclusion criteria apply only to:\n\n   Participants receiving one or more of the study drugs of interest at the time of enrollment, DOI administration or PK sampling: (Refer to DOI specific appendices for details on enrollment cohort specifications and additional eligibility criteria)\n2. Has had intermittent dialysis within previous 24 hours\n3. Has had a kidney transplant within previous 30 days\n4. Has had a liver transplant within previous 1 year\n5. Has had a stem cell transplant within previous 1 year\n6. Has had therapeutic hypothermia within previous 24 hours\n7. Has had plasmapheresis within the previous 24 hours\n8. Has a Ventricular Assist Device\n9. Has any condition which would make the participant, in the opinion of the investigator, unsuitable for the study","0 Years","20 Years",{"count":304,"type":21},5000,"The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose for children. The primary objective of this study is to evaluate the PK of understudied drugs currently being administered to children per SOC as prescribed by their treating provider.",[307,308,309,310,311,312,313,314,315,316,317,318,319,320,321,322,25,323,324,325,326,327,328,329,330],"Coronavirus Infection (COVID-19)","Pulmonary Arterial Hypertension","Urinary Tract Infections in Children","Hypertension","Pain","Hyperphosphatemia","Primary Hyperaldosteronism","Edema","Hypokalemia","Heart Failure","Hemophilia","Menorrhagia","Insomnia","Pneumonia","Skin Infection","Arrythmia","Bronchopulmonary Dysplasia","Adrenal Insufficiency","Fibrinolysis; Hemorrhage","Attention Deficit Hyperactivity Disorder","Multisystem Inflammatory Syndrome in Children (MIS-C)","Kawasaki Disease","Coagulation Disorder","Down Syndrome","2026-03-31",{"date":283,"type":32},{"date":334,"type":32},"2020-03-05",{"date":336,"type":21},"2027-07",{"name":338,"class":39},"Duke University",51,{"id":341,"slug":342,"hasResults":12,"nctId":343,"briefTitle":344,"officialTitle":345,"acronym":346,"eligibilityCriteria":347,"healthyVolunteers":12,"sex":17,"minAge":186,"maxAge":187,"enrollmentInfo":348,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":349,"conditions":350,"keywords":352,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":356,"lastUpdatePostDateStruct":357,"startDateStruct":359,"completionDateStruct":361,"leadSponsor":363,"locationsCount":65},"100572555","wearable-electronic-breath-sound-sensing-device-100572555","NCT06734793","Wearable Electronic Breath Sound Sensing Device","Pilot Study of Wearable Electronic Breath Sound Sensing Device for Monitoring of Breath Sounds in Pediatric Patients With Asthma","WEBSS","Inclusion Criteria:\n\n* Age 6-17 years\n* Diagnosis of persistent asthma\n* Being treated for an acute asthma exacerbation\n* Parent can speak and understand English\n\nExclusion Criteria:\n\n* Unable to provide consent for the study\n* History of prematurity\n* History of other chronic lung conditions - cystic fibrosis, bronchiectasis, or primary ciliary dyskinesia\n* History of latex allergy or allergy to medical tape adhesive\n* Patients currently using another medical device - implanted pacemaker or vagal nerve stimulator or diaphragm pacing device",{"count":7,"type":21},"This study will assess the ability of a wearable stethoscope to monitor wheezing in high-risk asthma patients admitted at Children's Healthcare of Atlanta.\n\nThis study is important to assist in the health management of patients with chronic lung diseases that can experience exacerbations leading to their health worsening and requiring hospitalization. The population that will be approached for this study will include 10 pediatric subjects hospitalized at Children's Healthcare of Atlanta for an asthma-related exacerbation. Participants will wear the patches for up to 8 hours on their chest and back wall from their date of consent until their hospital discharge. This may range from the participant taking part in 1 to 14 visits that could last up to 8 hours.",[25,351],"Asthma Attack",[353,354,355],"Hospital admission","Wearable stethoscope","Asthma Exacerbations","2026-03-22",{"date":358,"type":32},"2026-03-25",{"date":360,"type":32},"2025-02-26",{"date":362,"type":21},"2026-12-31",{"name":364,"class":39},"Emory University",{"id":366,"slug":367,"hasResults":12,"nctId":368,"briefTitle":369,"officialTitle":370,"acronym":4,"eligibilityCriteria":371,"healthyVolunteers":12,"sex":17,"minAge":73,"maxAge":48,"enrollmentInfo":372,"targetDuration":4,"studyType":50,"phases":373,"briefSummary":374,"conditions":375,"keywords":4,"overallStatus":109,"whyStopped":4,"lastUpdateSubmitDate":376,"lastUpdatePostDateStruct":377,"startDateStruct":379,"completionDateStruct":381,"leadSponsor":383,"locationsCount":4},"100496487","sbat-for-health-equity-100496487","NCT05744869","SBAT for Health Equity","School-based Asthma Therapy to Advance Health Equity Among Historically Marginalized Children","Inclusion Criteria:\n\n* Physician-diagnosed asthma, with persistent symptoms or poor control based on NHLBI criteria\n* Age \\>4 and \\\u003C12 years\n* Attending school in Rochester City School District\n* Caregiver \\>18 years, and is able to understand and speak English or Spanish\n\nExclusion Criteria:\n\n* Caregiver inability to speak and understand English or Spanish. (\\*Participants unable to read will be eligible, and all instruments will be given verbally.)\n* Having other significant medical conditions, including congenital heart disease, cystic fibrosis, or other chronic lung disease, that could interfere with the assessment of asthma-related measures.\n* In foster care or other situations in which consent cannot be obtained from a guardian.\n\nBased on our prior studies, fewer than 10% of subjects are expected to be excluded based on these criteria.",{"count":279,"type":21},[52],"The goal of this research trial is to: 1) Solidify a population health SBAT implementation strategy with our longstanding community collaborators, 2) Perform a district-wide hybrid type 3, stepped-wedge, cluster randomized trial, and 3) Assess the supportive resource utilization and essential features of SBAT to extend sustainability and fidelity in a cost-effective manner.",[25],"2026-03-19",{"date":378,"type":32},"2026-03-23",{"date":380,"type":21},"2026-08-01",{"date":382,"type":21},"2030-12-31",{"name":250,"class":39},{"id":385,"slug":386,"hasResults":12,"nctId":387,"briefTitle":388,"officialTitle":389,"acronym":390,"eligibilityCriteria":391,"healthyVolunteers":12,"sex":17,"minAge":73,"maxAge":48,"enrollmentInfo":392,"targetDuration":4,"studyType":50,"phases":394,"briefSummary":395,"conditions":396,"keywords":397,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":399,"lastUpdatePostDateStruct":400,"startDateStruct":402,"completionDateStruct":404,"leadSponsor":405,"locationsCount":65},"100515408","hospital-to-home-study-trial-to-optimize-transitions-and-address-disparities-in-asthma-care-100515408","NCT05991115","Hospital to Home Study: Trial to Optimize Transitions and Address Disparities in Asthma Care","The Hospital to Home Study: A Pragmatic Trial to Optimize Transitions and Address Disparities in Asthma Care","H2H","Inclusion Criteria:\n\n1. speak English or Spanish\n2. are at least 18 years old\n3. live in the District of Columbia, Maryland, or Virginia (DMV)\n4. have a child aged 4-12 years who is hospitalized due to asthma exacerbation.\n\nExclusion Criteria:\n\n1. . Children ages 4-12 years with chronic medical condition (other than asthma) including but not limited to diabetes, sickle cell disease, heart disease, lung disease or neurological disorder\n2. . Children ages 4-12 years involved in interventions with behavioral component and\u002For novel asthma therapeutics will be excluded given overlap with the current intervention\n3. . Children ages 4-12 years in foster care\n4. . Families not residing in the DMV\n5. . Caregivers who do not speak English or Spanish",{"count":393,"type":21},340,[52],"Caregiver-child dyads will be recruited during child's hospital admission for asthma exacerbation. Recruitment sites will be mainly Children's National Hospital Sheikh Zayed campus, as well as regional partners: Holy Cross Hospital, and Mary Washington Hospital. After enrollment, baseline data will be collected from caregiver. Caregiver-child dyads will be randomized (1:1 ratio) into the control arm or intervention arm. Control arm will receive the standard of care after hospital discharge. Intervention arm will receive the SOC plus an asthma navigator support after hospital discharge. Caregivers in both arms will complete data collection surveys (either in-person or via telehealth) at 3-,6-, 9-, and 12- month post enrollment.",[55,25],[136,398,198],"hospitalization","2026-03-16",{"date":401,"type":32},"2026-03-17",{"date":403,"type":32},"2024-01-22",{"date":336,"type":21},{"name":406,"class":39},"Kavita Parikh",{"id":408,"slug":409,"hasResults":12,"nctId":410,"briefTitle":411,"officialTitle":412,"acronym":4,"eligibilityCriteria":413,"healthyVolunteers":12,"sex":17,"minAge":186,"maxAge":187,"enrollmentInfo":414,"targetDuration":4,"studyType":50,"phases":416,"briefSummary":418,"conditions":419,"keywords":420,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":435,"lastUpdatePostDateStruct":436,"startDateStruct":438,"completionDateStruct":440,"leadSponsor":442,"locationsCount":65},"100544696","phase-2-a-clinical-trial-of-soluble-fiber-for-asthma-100544696","NCT06372249","A Clinical Trial of Soluble Fiber for Asthma","A Phase ll Randomized Controlled Trial of Soluble Fiber for Asthma","Inclusion Criteria:\n\n* Between ages 6-17\n* Asthma diagnosis within the last 2 years\n* Fractional excretion of exhaled nitric oxide (FeNO) \\> 50 ppb OR a clinical history of environmental allergies as defined by a positive skin prick or positive specific immunoglobulin E (IgE) tests to aeroallergens\n* No emergency department visits in the past 1 month\n* Ability to consume a liquid drink of fiber or placebo\n* Ability to return for a 4-6 week follow-up visit\n* No special or unique diet\n\nExclusion Criteria:\n\n* Cystic fibrosis\n* Bronchiectasis\n* Change in asthma medicines other than short acting bronchodilators planned over the next 4-6 weeks\n* Baseline estimated daily fiber intake less than or equal to 16 grams as determined by the ASA 24\n* Sibling of a participant already enrolled in the study",{"count":415,"type":21},105,[417],"PHASE2","Randomized controlled trial of soluble fiber (Fruitafit Inulin). Participants will complete an ASA 24 dietary recall questionnaire to access their fiber intake. If eligible for the study, participants will be supplemented to their target fiber dosage with either soluble fiber (Fruitafit Inulin) or placebo. Collection of blood serum, fecal samples, and nasal wash will aid in analyzing the microbes present in one's gut and how fiber and diet may impact it. Thus, allowing researchers to better understand the pathways that may connect diet and asthma and if it is possible to improve asthma by altering one's diet.",[25],[55,421,422,423,424,425,426,427,428,429,430,431,432,82,433,434],"Mild Asthma","Moderate Asthma","Severe Asthma","Allergies","Environmental Allergies","Controlled Asthma","Well-Controlled Asthma","Diet","Dietary Fiber","Dietary Supplementation","Micro-biome","Gut-microbiome","Child","Microbiome Analysis","2026-03-02",{"date":437,"type":32},"2026-03-04",{"date":439,"type":32},"2025-11-10",{"date":441,"type":21},"2027-05-31",{"name":443,"class":39},"Phoenix Children's Hospital",{"id":445,"slug":446,"hasResults":12,"nctId":447,"briefTitle":448,"officialTitle":449,"acronym":4,"eligibilityCriteria":450,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":451,"targetDuration":4,"studyType":50,"phases":453,"briefSummary":454,"conditions":455,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":457,"lastUpdatePostDateStruct":458,"startDateStruct":460,"completionDateStruct":462,"leadSponsor":464,"locationsCount":65},"100564039","the-exhale-study-treating-maternal-depression-in-an-urban-pediatric-asthma-clinic-100564039","NCT06623981","The Exhale Study: Treating Maternal Depression in an Urban Pediatric Asthma Clinic","Testing the Effectiveness and Implementation of an Evidence-Based Maternal Depression Treatment in an Urban Pediatric Asthma Clinic","Inclusion Criteria:\n\nMaternal:\n\n* Primary caregiver of the child with asthma seen at the community-based asthma clinic\n* Female (self-identified)\n* Black (self-identified)\n* ≥ 18 years of age\n* English-speaking\n* PHQ-9 ≥ 8 during standardized screening at the child with asthma's clinic visit\n\nChild:\n\n* \\\u003C18 years old for the duration of the 6-month study period\n* Publicly insured\n* Physician-diagnosed persistent asthma\n\nExclusion Criteria:\n\nMaternal:\n\n* Acutely suicidal (high risk on the C-SSRS at child's asthma clinic visit)\n* Bipolar disorder or mania\n* Schizophrenia\n* Current substance abuse\u002Fdependence\n* Current serious physical intimate partner violence (IPV)\n* Lack of capacity to meaningfully participate in study procedures, as assessed by study staff during screening\n\nChild:\n\n* Significant medical co-morbidity (e.g., disorders of the cardiorespiratory system, significant developmental delay, diabetes, seizure disorder, and sickle cell disease)\n* Enrolled in another intervention with a behavioral component and\u002For novel asthma therapeutics",{"count":452,"type":21},60,[52],"The goal of this clinical trial is to test the effectiveness and implementation of delivering Enhanced Brief Interpersonal Psychotherapy (IPT-B), an evidence-based maternal depression treatment, to mothers of children under the age of 18 in an urban pediatric asthma clinic. Researchers will compare Enhanced IPT-B and supplemented usual care (brief care coordination). The main questions the trial aims to answer are:\n\n1. Does Enhanced IPT-B decrease maternal depressive symptoms?\n2. Does Enhanced IPT-B improve child asthma management and health outcomes (exacerbations, symptoms, control)?\n3. What are the preliminary implementation outcomes of delivering Enhanced IPT-B in an urban pediatric asthma clinic?",[25,456],"Depression","2026-02-23",{"date":459,"type":32},"2026-02-24",{"date":461,"type":32},"2024-10-15",{"date":463,"type":21},"2027-03-15",{"name":465,"class":39},"Children's National Research Institute",{"id":467,"slug":468,"hasResults":12,"nctId":469,"briefTitle":470,"officialTitle":471,"acronym":4,"eligibilityCriteria":472,"healthyVolunteers":12,"sex":17,"minAge":186,"maxAge":187,"enrollmentInfo":473,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":471,"conditions":474,"keywords":478,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":480,"lastUpdatePostDateStruct":481,"startDateStruct":483,"completionDateStruct":485,"leadSponsor":486,"locationsCount":40},"100624679","asmact-study-on-management-of-bronchial-asthma-100624679","NCT07412769","ASMact: Study on Management of Bronchial Asthma","Standardization According to GINA 2025 Recommendations for the Treatment, Management, and Follow-up of Acute Asthma Attacks: Observational, Multicenter Cohort Study.","Inclusion Criteria:\n\n* Age between 6 and 17 years\n* Presentation to the emergency department with a diagnosis of acute asthma exacerbation\n* Evaluation in the emergency department of one of the participating centers during the study periods\n\nExclusion Criteria:\n\n* Age \\\u003C 6 years or \\> 17 years\n* Diagnosis other than acute asthma exacerbation\n* Incomplete or missing clinical data\n* Patients transferred from other hospitals already treated for the same episode\n* history of allergy to any drugs used in the protocol",{"count":20,"type":21},[475,476,25,477],"Asthma Acute","Asthma Childhood","Asthma Crisis",[479],"asthma attack, exacerbation,","2026-02-13",{"date":482,"type":32},"2026-02-17",{"date":484,"type":32},"2025-11-05",{"date":57,"type":21},{"name":487,"class":39},"Meyer Children's Hospital IRCCS",{"id":489,"slug":490,"hasResults":12,"nctId":491,"briefTitle":492,"officialTitle":493,"acronym":494,"eligibilityCriteria":495,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":496,"enrollmentInfo":497,"targetDuration":4,"studyType":50,"phases":499,"briefSummary":500,"conditions":501,"keywords":502,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":480,"lastUpdatePostDateStruct":505,"startDateStruct":506,"completionDateStruct":508,"leadSponsor":510,"locationsCount":65},"100519477","dynamics-of-the-upper-and-lower-airway-respiratory-microbiomes-associated-with-severe-infant-asthma-100519477","NCT06044051","Dynamics of the Upper and Lower Airway Respiratory Microbiomes Associated With Severe Infant Asthma","Dynamique Des Microbiomes Respiratoires Des Voies supérieures et inférieures associée à l'Asthme sévère Des Nourrissons","Microbiosthme","Inclusion Criteria:\n\n* Infants less than 24 months old\n* Follow-up by a pneumo-pediatrician for severe asthma in infants\n* Requiring etiological investigations and assessment of severity in day hospitalization, including bronchial fibroscopy (HAS 2009)\n* Parent informed of the research and having signed consent\n\nExclusion Criteria:\n\n* Prematurity \\\u003C32 WA\n* Congenital heart disease with significant left to right shunt\n* Chronic respiratory disease other than infant asthma (cystic fibrosis, bronchiolitis obliterans)\n* Antibiotic therapy in progress or administered the seven days preceding the date of inclusion (day hospitalization)\n* Refusal of bronchial fibroscopy","24 Months",{"count":498,"type":21},100,[52],"Nature of potential dysbiosis, interrelation of the different microbiomes of the respiratory tract, and potential role of the immune system in the pathogenesis of severe asthma in infants, and its evolution under treatment.\n\nExploring and understanding these data is to improve patient care and discover new therapeutic targets.\n\nThe aim is to open up prospects for therapeutic studies, such as the use of azithromycin as an immunomodulator in infant asthma, the results of which are discordant.",[25,55],[503,504],"microbiosme","Asthma in infant",{"date":482,"type":32},{"date":507,"type":32},"2023-09-26",{"date":509,"type":21},"2026-09-26",{"name":511,"class":39},"University Hospital, Rouen",{"id":513,"slug":514,"hasResults":12,"nctId":515,"briefTitle":516,"officialTitle":517,"acronym":4,"eligibilityCriteria":518,"healthyVolunteers":12,"sex":17,"minAge":186,"maxAge":48,"enrollmentInfo":519,"targetDuration":4,"studyType":50,"phases":521,"briefSummary":522,"conditions":523,"keywords":4,"overallStatus":109,"whyStopped":4,"lastUpdateSubmitDate":524,"lastUpdatePostDateStruct":525,"startDateStruct":527,"completionDateStruct":529,"leadSponsor":531,"locationsCount":4},"100577291","smart-school-based-asthma-therapy-100577291","NCT06796387","SMART-School-based Asthma Therapy","SMART-SBAT: Transforming Pediatric Asthma Care Through School-Based Single-Inhaler Therapy","Inclusion Criteria:\n\n* Physician-diagnosed asthma, with moderate-severe persistent symptoms or poor control based on NHLBI criteria\n* Age \\>=6 and =\\\u003C12 years\n* Attending school in Rochester City School District\n* Caregiver \\>=18 years, and is able to understand and speak English or Spanish\n\nExclusion Criteria:\n\n* Caregiver inability to speak and understand English or Spanish. (\\*Participants unable to read will be eligible, and all instruments will be given verbally.)\n* Having other significant medical conditions, including congenital heart disease, cystic fibrosis, or other chronic lung disease, that could interfere with the assessment of asthma-related measures.\n* In foster care or other situations in which consent cannot be obtained from a guardian.\n\nBased on prior studies, fewer than 10% of subjects are expected to be excluded based on these criteria.",{"count":520,"type":21},330,[52],"The goal of this research trial is to: 1) Develop a SMART-SBAT protocol specifically designed for schools, 2) Evaluate the effectiveness of SMART-SBAT vs. usual care using a district wide, stepped-wedge type 1 cluster randomized trial and 3) Evaluate the process of implementing SMART-SBAT to contextualize effectiveness outcomes and inform future scale-up.",[25],"2026-01-27",{"date":526,"type":32},"2026-01-29",{"date":528,"type":21},"2026-12",{"date":530,"type":21},"2031-12",{"name":250,"class":39},{"id":533,"slug":534,"hasResults":12,"nctId":535,"briefTitle":536,"officialTitle":537,"acronym":538,"eligibilityCriteria":539,"healthyVolunteers":12,"sex":17,"minAge":48,"maxAge":18,"enrollmentInfo":540,"targetDuration":4,"studyType":50,"phases":542,"briefSummary":543,"conditions":544,"keywords":545,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":550,"lastUpdatePostDateStruct":551,"startDateStruct":553,"completionDateStruct":555,"leadSponsor":557,"locationsCount":40},"100581546","improving-quality-of-life-for-teenagers-with-asthma-100581546","NCT06851715","Improving Quality of Life for Teenagers With Asthma","Can the Quality of Life of Adolescents With Asthma be Improved by Focusing on Improving Their Asthma Self-management","IMPAQT","Inclusion Criteria:\n\n* Adolescent aged 12-18 years\n* Attending a paediatric respiratory clinic\n* Informed consent from adolescent aged ≥16 years, and assent plus parent\u002Fguardian consent for adolescents aged ≤16 years\n* Paediatric Asthma Quality of Life Questionnaire score ≤5.5 points\n\nExclusion Criteria:\n\n* Aged 0-11 or over 18 years\n* Other significant long-term medical condition that has a day-to-day impact on their lives (except for co-existing allergic conditions, breathing pattern disorder, dysfunctional breathing, or intermittent laryngeal obstruction)\n* Adolescent or parent\u002Fguardian unable to communicate sufficiently to complete consent forms.",{"count":541,"type":21},98,[52],"BACKGROUND: Asthma is a long-term lung condition affecting 1 in 11 children and young people in the UK. Many teenagers have well controlled asthma, but a significant number continue to experience regular symptoms and asthma attacks leading to hospitalisations. While non-adherence to medication is a factor, teenagers also face challenges like changing relationships with parents and peers, avoiding triggers like smoking, and fitting in treatment with daily life demands. Healthcare professionals (HCPs) also face difficulties in managing teenagers with asthma.\n\nA previous study, funded by Asthma + Lung UK, developed a new approach to manage teenage asthma by focusing on self-efficacy, which is how confident one feels about performing a task. Teenagers completed the Adolescent Asthma Self-Efficacy Questionnaire (AASEQ), which identified areas where they needed more support. HCPs then tailored their consultations to address these needs. This approach improved the teenagers' confidence in self-managing their asthma.\n\nImproving quality of life (QoL) is a key goal in asthma care. Therefore, the aim of this study is to determine if the self-efficacy approach improves QoL for teenagers with asthma.\n\nMETHODS: Teenagers aged 12-18 years with asthma will be recruited from hospital clinics. They will be randomly assigned to one of two groups:\n\n1. Teenager will complete the AASEQ at the start of their appointment. The HCPs will use this to focus the consultation on areas where the teenager needs support in self-managing their asthma.\n2. Teenager will have their usual consultation with the HCP.\n\nThree months after the appointment, the QoL will be compared between the two groups using a standardised questionnaire.\n\nIMPACT: If the self-efficacy approach proves to be beneficial, it could help HCPs to empower teenagers to better manage their asthma and ultimately improve their quality of life.",[25,55],[55,546,547,548,549],"Adolescent","Self-efficacy","Quality of life","Asthma control","2025-12-30",{"date":552,"type":32},"2026-01-05",{"date":554,"type":32},"2025-08-26",{"date":556,"type":21},"2027-11-01",{"name":558,"class":39},"University Hospital Southampton NHS Foundation Trust",{"id":560,"slug":561,"hasResults":12,"nctId":562,"briefTitle":563,"officialTitle":563,"acronym":564,"eligibilityCriteria":565,"healthyVolunteers":154,"sex":17,"minAge":566,"maxAge":567,"enrollmentInfo":568,"targetDuration":4,"studyType":50,"phases":570,"briefSummary":571,"conditions":572,"keywords":573,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":577,"lastUpdatePostDateStruct":578,"startDateStruct":580,"completionDateStruct":582,"leadSponsor":583,"locationsCount":40},"100490559","phase-2-soy-isoflavones-for-inner-city-infants-at-risk-for-asthma-sira-study-100490559","NCT05667701","Soy Isoflavones For Inner City Infants At Risk For Asthma (SIRA) Study","SIRA","Inclusion Criteria:\n\n1. Parent\u002Fguardian must be an adult (≥18 years of age) and able to understand and provide informed consent.\n2. Age: Term infants (≥37 weeks gestational age) less than 12 months of age at recruitment\n3. High risk of asthma: As determined by one or more of the following:\n\n   1. A history of uni- or bi-parental asthma with onset in childhood by parent self report, OR\n   2. Uni- or bi-parental asthma with onset after childhood along with the presence of one or more other comorbid atopic condition including allergic rhinitis, atopic dermatitis, or food allergy, OR\n   3. atopic dermatitis in the child determined by parent report of a physician diagnosis\n4. Genotype: Either homozygous or heterozygous for the PAI-1 risk allele (i.e. 4G4G or 4G5G).\n5. Have a primary place of residence in one of the pre-selected recruitment census tracts as outlined in the SIRA Manual of Operations (MOP).\n\n   1. Participants who do not live in the pre-selected census tracts but live within the Office of Management and Budget (OMB) defined Metropolitan Statistical Area and have publicly funded health insurance will qualify for inclusion.\n\nExclusion Criteria:\n\n1. 1\\. Inability or unwillingness of a parent or guardian to give written informed consent or comply with study protocol.\n2. Parents who will not include either a puree or some form of bottle feeding such that the infant would be able to take the investigational product in a puree or a liquid (expressed breast milk, supplemental formula, or a small amount of water).\n3. Currently on a soy based formula.\n4. Breastfeeding mothers who are taking soy supplements or soy enriched foods more than 2 times a week and will not stop this level of ingestion while breastfeeding.\n5. On treatment for recurrent wheezing such as regular inhaled steroids.\n6. The infant may not have the following specific contraindications: known congenital thyroid disease, or a history of estrogen sensitive clinically relevant mutations in the family (such as BRCA1).\n7. Medication use\n\n   1. Maternal use of tamoxifen in pregnancy or if breastfeeding\n   2. Use of immunomodulatory medications such at methotrexate, mycophenolate, azathioprine, or other immunomodulatory agent in the mother if breastfeeding or in the infant.\n8. Use of another investigational agent in the last 30 days prior to randomization.\n9. Current, parent reported, diagnosis of mental illness or current, diagnosed or self-reported drug or alcohol abuse (in the primary caregiver) that, in the opinion of the investigator, would interfere with the participant's ability to comply with study requirements.\n10. Known allergy to soy protein (either by reported allergy or skin testing to soy prior to randomization) or reported allergy to NovaSoy, from which the investigational product is compounded.\n11. The infant is currently participating in another asthma-related pharmaceutical study or intervention study or who have participated in another asthma-related pharmaceutical study or intervention study in the month prior to enrollment.\n12. Past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study.\n13. Infant requiring intubation prior to screening.\n14. Infant requiring \\> 3 hospitalizations for asthma symptoms\u002F wheezing illness prior to screening.\n15. Infant requiring \\> 3 five day bursts of oral steroid at least 14 days apart from each other prior to screening.\n16. Any chronic condition requiring use of systemic corticosteroids or another immunomodulating agent at screening or before randomization, and during the course of the study.\n17. Non-adherence:\n\n    1. Inability \u002F unwillingness of the parents to induce the infant to swallow study medication\n    2. Unwillingness of the parents to allow the staff to perform baseline measurements\n18. Living with a foster parent as a ward of the state.\n19. Caregiver does not have access to a phone (needed for scheduling appointments or responding to questionnaires).\n20. Plan(s) for the family to move from the area during the study period.\n21. The infant's caretaker does not primarily speak English or Spanish.\n\nIn order to be eligible to continue in the study following screening visit A (V1) , an individual must meet all of the following additional randomization criteria:\n\n1. Must be ≥4 months and \\\u003C12 months of age at randomization\n2. Must have either 4G\u002F4G or 4G\u002F5G genotype\n3. Cannot have had a severe wheezing exacerbation requiring ICU admission between screening (V1) and randomization (V3)\n4. Cannot have had more than two wheezing \u002F \"asthma\" episodes (separated from each other by at least 14 days), each requiring at least a 5 day course of oral steroids in the time between screening visit A (V1) and randomization (V3).","2 Months","12 Months",{"count":569,"type":21},65,[417],"The goal of this clinical trial is to compare soy isoflavones to placebo in children who at risk of asthma and have a genetic variation which results in them making more of a pro-inflammatory protein, plasminogen activator inhibitor-1. The main questions this trail seeks to answer is: will soy isoflavones decrease the proportion of infants with aT2 high endotype at the end of treatment, and secondarily decrease the number of wheezing episodes in these children when given in the first year of life. Participants will be asked to ingest soy isoflavone or placebo twice daily mixed into a liquid or puree vehicle for 7 months from randomization. There will be 3 mandatory in-person visits, and 6 virtual visits in the first year. There will also be 11 monthly questionnaires and 1 in person visit in the observation year. Participants will have 4 nasal swabs, 3 blood draws, and also provide 4 stool samples over the course of the study.",[162,25],[574,575,576],"wheezing","soy isoflavone","PAI-1","2025-11-18",{"date":579,"type":32},"2025-11-21",{"date":581,"type":32},"2024-09-18",{"date":176,"type":21},{"name":584,"class":39},"Rajesh Kumar",{"id":586,"slug":587,"hasResults":12,"nctId":588,"briefTitle":589,"officialTitle":590,"acronym":591,"eligibilityCriteria":592,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":187,"enrollmentInfo":593,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":594,"conditions":595,"keywords":598,"overallStatus":109,"whyStopped":4,"lastUpdateSubmitDate":600,"lastUpdatePostDateStruct":601,"startDateStruct":602,"completionDateStruct":604,"leadSponsor":606,"locationsCount":4},"100610820","biomarkers-and-respiratory-omics-as-new-children-opportunities---study-of-clinical-outcomes-and-predictivity-evaluation-100610820","NCT07232550","Biomarkers and Respiratory Omics as New CHildren Opportunities - Study of Clinical Outcomes and Predictivity Evaluation","Biomarkers and Respiratory Omics as New CHildren Opportunities - Study of Clinical Outcomes and Predictivity Evaluation - a Multi-cohort, Multi-center Study","BRONCHOSCOPE","Inclusion Criteria:\n\n* Age at the beginning of the study 0-17 years old\n* Clinical indication and qualification by the attending physician for fiberoptic bronchoscopy under general anesthesia:\n\n  * Obstruction of the airways:\n  * Suspicion of foreign body aspiration\n  * Persistent stridor\n  * Abnormal result of functional tests of respiratory system - flattening of inspiratory or expiratory curve, presence of restriction (tested vital capacity \\\u003C5 percentile) or irreversible obstruction (persistence of Tiffneau index \\\u003C5 percentile despite administration of bronchodilators)\n  * Radiological findings located in the course of the larynx, trachea or bronchi\n  * Persistent atelectasis on subsequent radiological examinations\n  * Persistent cough \\>4 weeks\n  * Hemoptysis\n  * Suspected laryngomalacia or tracheobronchomalacia\n  * Suspected tracheoesophageal fistula\n  * Persistent dyspnea unresponsive to anti-asthmatic treatment used for min. 2 months, with no other identifiable causes\n  * Radiologically detected mediastinal abnormalities\n  * Suspected presence of a vascular ring\n  * Presence of excessive secretions that are impossible for the patient to expectorate\n  * Fine needle biopsy of cystic lesions\n* Obtained consent from patient\u002Flegal guardian for participation in the study\n\nExclusion Criteria:\n\n* Active acute respiratory infection up to 4 weeks before the procedure\n* Taking antibiotics or systemic glucocorticosteroids up to 4 weeks before the procedure\n* Patients with very severe comorbidities (congenital immunodeficiencies, genetic disorders, neurological or neuromuscular diseases, cancer, severe congenital heart defects, heart failure, liver failure, inflammatory bowel disease, celiac disease)\n* Patients with blood clotting disorders\n* Children with diagnosed respiratory diseases other than asthma and protracted bacterial bronchitis - including interstitial diseases, tuberculosis, inflammation of small and medium-sized blood vessels\n* Patients for whom \\>48 hours have passed between suspicion of foreign body aspiration and interventional bronchoscopy\n* Children with foreign body aspiration having a foreign body located in the trachea",{"count":157,"type":21},"The goal of this observational study is to improve the identification of biomarkers that predict disease progression and to assess the effectiveness of current therapies in children with asthma and protracted bacterial bronchitis.\n\nThe main aim of the study is to evaluate the microbiome composition and diversity, cellular composition, and metabolomic profile. In addition, to assess their correlation on subsequent treatment and disease course in children with asthma, protracted bacterial bronchitis, and in those receiving inhaled glucocorticosteroids without a diagnosis of asthma.\n\nParticipants will undergo fiberoptic bronchoscopy. During bronchoscopy, the performing physician will collect Bronchoalveolar lavage fluid samples for metagenomic and metabolomic analysis, as well as mucosal biopsies for histopathological evaluation.",[25,596,597],"Protracted Bacterial Bronchitis","Chronic Cough",[599,55],"PBB","2025-11-14",{"date":577,"type":32},{"date":603,"type":21},"2025-11",{"date":605,"type":21},"2035-12",{"name":607,"class":39},"Medical University of Warsaw",{"id":609,"slug":610,"hasResults":12,"nctId":611,"briefTitle":612,"officialTitle":613,"acronym":614,"eligibilityCriteria":615,"healthyVolunteers":12,"sex":17,"minAge":73,"maxAge":187,"enrollmentInfo":616,"targetDuration":4,"studyType":50,"phases":617,"briefSummary":618,"conditions":619,"keywords":622,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":600,"lastUpdatePostDateStruct":624,"startDateStruct":625,"completionDateStruct":627,"leadSponsor":629,"locationsCount":65},"100549344","comparative-effectiveness-of-a-healthy-lifestyle-and-asthma-management-program-in-person-vs-online-100549344","NCT06432790","Comparative-effectiveness of a Healthy Lifestyle and Asthma Management Program, In-person vs. ONline","Comparative-effectiveness of a Healthy Lifestyle and Asthma Management Program, In-person vs. ONline (CHAMPION)","CHAMPION","Caregiver-proxies will be 18 years old or older, English or Spanish speaking, and a primary caregiver of a child meeting the following criteria:\n\nInclusion criteria\n\n* Age 4-17.9 years at time of screening\n* BMI ≥ 85th percentile\n* Asthma or reactive airway disease diagnosis, per child's Electronic Health Record (EHR) documentation and caregiver report\n\nExclusion criteria\n\n* Diagnosis of anorexia nervosa, per child's EHR or caregiver report\n* Pregnant, per child's EHR\n* Plan to change pediatricians in the next year, per caregiver report\n* Opted out of research, per child's EHR\n* Sibling currently enrolled in the research trial, per enrollment log or caregiver report",{"count":20,"type":21},[52],"The goal of this study is to evaluate the effectiveness of CHAMPION (\"Comparative-effectiveness of a Healthy lifestyle and Asthma Management Program, In-person vs ONline\"), a primary care-based intervention to address childhood obesity and asthma, and test the effectiveness of a telehealth-only version of the program. Intensive Health Behavior and Lifestyle Treatment (IHBLT), when delivered via telehealth vs. in-person among children with overweight or obesity and persistent asthma.",[620,621,25],"Overweight, Childhood","Obesity, Childhood",[623],"telehealth",{"date":577,"type":32},{"date":626,"type":32},"2024-07-17",{"date":628,"type":21},"2028-07-31",{"name":630,"class":39},"Massachusetts General Hospital",{"id":632,"slug":633,"hasResults":12,"nctId":634,"briefTitle":635,"officialTitle":636,"acronym":637,"eligibilityCriteria":638,"healthyVolunteers":12,"sex":17,"minAge":496,"maxAge":639,"enrollmentInfo":640,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":641,"conditions":642,"keywords":643,"overallStatus":109,"whyStopped":4,"lastUpdateSubmitDate":645,"lastUpdatePostDateStruct":646,"startDateStruct":648,"completionDateStruct":649,"leadSponsor":651,"locationsCount":207},"100592048","early-identification-of-children-with-asthma-100592048","NCT06988358","Early Identification of Children With Asthma","Early Identification of Children With Asthma in Electronic Medical Records in Primary Care","IDEA","Inclusion Criteria:\n\n* Children aged 2 years 0 days to 5 years 11 months and 30 days inclusive\n* Consultation in one of the 4 Maisons de Santé Pluriprofessionnelle connected to the PRIMEGE Normandie primary care data warehouse: Neufchâtel-en-Bray, Val-de-Reuil, Le Grand-Quevilly and Rouen Carmes.\n* At least two consultations between the ages of 2 and 5, with a general practitioner in the same care setting\n* Parents having been informed of the use of data from electronic medical records and having expressed no objection to the use of this data\n\nExclusion Criteria:\n\n* Children under 2 years of age\n* Children aged 6 years 0 days and over\n* Recourse by a patient's legal representative to one of the RGPD rights restricting the use of their data in the context of research","71 Months",{"count":279,"type":21},"GPs are one of the key players in the early diagnosis of chronic diseases, such as asthma in pre-school children, by detecting symptoms of illness as early as possible. Patient health data is collected on an ongoing basis in GPs' electronic medical records, but remains little exploited despite its potential.\n\nHelping GPs to identify asthma in pre-school children, based on the information in their electronic medical records, could help them to diagnose the condition early and thereby reduce the morbidity and mortality associated with it.\n\nAn algorithm developed and evaluated in a primary care data warehouse should help GPs to identify children with a diagnosis of asthma at an early stage.",[25],[644],"Predictive algorithm","2025-09-26",{"date":647,"type":32},"2025-10-02",{"date":550,"type":21},{"date":650,"type":21},"2027-06-30",{"name":511,"class":39}]